Monthly Archives: March 2019

Gilde Healthcare raises €200 million for new private equity fund

GIlde Healthcare

Targeting lower mid-market healthcare investments in the Benelux and DACH regions

Utrecht (the Netherlands) and Frankfurt (Germany) – Gilde Healthcare, the European specialist investor in healthcare, today announces that it has raised €200 million for its third private equity fund, Gilde Healthcare Services III. The fund will focus on healthcare providers, suppliers of medical products and service providers in the lower mid-market. The fund operates offices in Utrecht (The Netherlands) and Frankfurt (Germany).

The fund reached its hardcap in a few months’ time and was raised with Dutch institutional investors including, among others, PGGM/Pensioenfonds Zorg en Welzijn and Rabo Corporate Investments and various international fund-of-fund investors. To date, Gilde Healthcare has raised more than €1 billion for its dedicated healthcare investment funds. Examples of recent private equity investments include hospital software provider Performation, integrated telecom solutions provider Zetacom and drug discovery contract research organization MercachemSyncom.

Jasper van Gorp, Managing Partner at Gilde Healthcare: “We are pleased with the high level of interest for our new fund which is testament to our investment strategy and track record. We see a strong deal flow of healthcare providers, suppliers of medical products and service providers in the Benelux and DACH regions. Via our local presence we are well-positioned to source proprietary healthcare transactions in the lower mid-market.”

The new private equity fund is focused on established and profitable businesses in Europe with an EBITDA of between €2-15 million, preferably headquartered in the Benelux or DACH (Germany, Switzerland and Austria) regions.

In addition to capital, Gilde Healthcare provides hands-on support to the management of its portfolio companies, via activities such as implementing a growth strategy and leveraging its deep healthcare industry expertise and international network. Gilde Healthcare believes optimal value creation in healthcare is associated with better care at lower cost.

Recently, Gilde Healthcare strengthened its private equity team with additional experienced investment professionals: Rafael Natanek (previously a partner at Bain Consulting in the European healthcare practice) joined as partner and Boyd Rutten (previously at private equity firm EQT Partners) joined as senior associate.
About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two fund strategies: private equity and venture & growth capital. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies including healthcare providers, suppliers of medical products and service providers, with a primary focus on the Benelux and DACH regions. Gilde Healthcare’s venture & growth fund is focused on fast growing health tech and therapeutics companies based in Europe and North America. https://gildehealthcare.com

Media Contacts

Gilde Healthcare

Jasper van Gorp
Managing Partner
Newtonlaan 91
3584BP Utrecht
The Netherlands
vangorp@gildehealthcare.com
+31 (0)30 219 2533

Dr Fabian Braemisch
Partner DACH-region
Neue Mainzer Strasse 74
60594 Frankfurt
Germany
braemisch@gildehealthcare.com
+49 69 153 255 870

CFF Communications

Jan van Ewijk
+31 (0)20 575 4011
+31 (0)6 14229820
jan.vanewijk@cffcommunications.nl

Aniek Zweers
+31 (0)20 575 4032
+31 (0)6 31973375
aniek.zweers@cffcommunications.nl

Categories: News

Platinum Equity to Acquire Spanish Seafood Provider Iberconsa from Portobello Capital

Platinum

LOS ANGELES (March 7, 2019) – Platinum Equity today announced the signing of a definitive agreement to acquire a majority stake in Grupo Ibérica de Congelados, S.A. (“Iberconsa”) from Portobello Capital and affiliates of the company’s founding families. The sellers and members of the Iberconsa management team will be minority investors alongside Platinum Equity. Financial terms were not disclosed. The transaction is expected to close in Q2 2019.

Headquartered in Vigo, Spain, Iberconsa is a global provider of frozen seafood products, including hake, Argentine red shrimp and squid. The company is vertically integrated across the full value chain, including wild catch, processing, commercialization and distribution.

“Iberconsa has established itself as a leader in the markets it currently serves,” said Platinum Equity Partner Louis Samson. “The company has grown substantially in recent years and can benefit from Platinum’s operational expertise to help maximize the benefits of its increased scale. We also intend to further grow the business through new acquisitions by deploying our M&A resources to help the management team expand the company’s product portfolio and geographic reach.”

Iberconsa maintains an owned fleet of 45 vessels, five processing plants and four cold storage distribution facilities. Iberconsa’s fleet operates primarily in Argentina, Namibia and South Africa, and the company’s products are sold in more than 60 countries.

“Iberconsa has established itself as a leader in the markets it currently serves,” said Platinum Equity Partner Louis Samson. “The company has grown substantially in recent years and can benefit from Platinum’s operational expertise to help maximize the benefits of its increased scale. We also intend to further grow the business through new acquisitions by deploying our M&A resources to help the management team expand the company’s product portfolio and geographic reach.”

“We are proud of everything Iberconsa has accomplished during our ownership, expanding its fleet and establishing itself as a strong platform for additional growth in a fragmented market,” said Juan Luis Ramírez, Founding Partner at Portobello Capital. “We are re-investing in the business because we believe it is well positioned for continued success.”

Iberconsa CEO Alberto Freire will continue to lead the business following the transfer of ownership.

“We believe in the future of our company and are confident that Platinum Equity is the right partner to help us achieve the next stage of growth and expansion,” said Mr. Freire.

Platinum Equity’s proposed acquisition of Iberconsa is the latest example of the firm’s increasing momentum in Europe. Last year Platinum Equity completed the $2.1 billion acquisition of Zug, Switzerland and Chesterbrook, PA-based blood glucose monitoring company LifeScan from Johnson & Johnson. The firm also acquired Wyndham’s European vacation rental business for $1.3 billion.

Platinum Equity sold Exterion Media to British media and entertainment group Global in November 2018, and sold Paris-based Worldwide Flight Services to Cerberus Capital Management, L.P. in October 2018 in a transaction valued at approximately €1.2 billion.

Lazard and Deloitte are serving as financial advisors to Platinum Equity on the acquisition of Iberconsa. Latham & Watkins is serving as Platinum Equity’s legal advisor on the transaction.

Nomura and Ernst & Young (“E&Y”) are serving as financial advisors to the sellers. E&Y is also serving as the sellers’ legal advisor on the transaction.

About Platinum Equity
Founded in 1995 by Tom Gores, Platinum Equity is a global investment firm with approximately $13 billion of assets under management and a portfolio of approximately 40 operating companies that serve customers around the world. The firm is currently investing from Platinum Equity Capital Partners IV, a $6.5 billion global buyout fund, and Platinum Equity Small Cap Fund, a $1.5 billion buyout fund focused on investment opportunities in the lower middle market. Platinum Equity specializes in mergers, acquisitions and operations – a trademarked strategy it calls M&A&O® – acquiring and operating companies in a broad range of business markets, including manufacturing, distribution, transportation and logistics, equipment rental, metals services, media and entertainment, technology, telecommunications and other industries. Over the past 23 years Platinum Equity has completed more than 250 acquisitions.

About Portobello Capital
Founded in 2010, Portobello Capital is a leading independent Mid-Market Private Equity manager based in Spain that invests in Southern Europe. It has €1.3 billion of assets under management, a team of 27 professionals and 15 companies in its portfolio (Angulas Aguinaga, Centauro and Vivanta, among others). Portobello Capital manages two primary funds: Fund III was closed at €375 million in August 2014 and it is fully invested, and Fund IV closed in February 2018 and is currently being invested. Portobello Capital is also managing a secondary vehicle with €300 million.

Categories: News

Tags:

Connected Capital leads investment in ChannelSight

Connected Capital
ChannelSight , the Dublin-based leaders in ‘Where to Buy’ technology for large brands has closed a Series-B financing round of $10 million, led by Connected Capital, the Amsterdam-based B2B SaaS investor. Channelsight will use this round to consolidate its global ‘Where-to-Buy’ leadership position.

Founded in 2013, ChannelSight’s platform enables brands such as Philips, Bosch, Pepsi and Mondelez to drive sales from their digital content and understand what content and ads work most effectively across all digital channels. Existing investors include Nauta Capital, ACT Venture Capital and Enterprise Ireland, all of whom participated in this latest fundraising round. This round of financing will accelerate ChannelSight’s product roadmap delivery and global expansion.

“ChannelSight’s solution is innovative – it strengthens digital reach and increases sales conversions while providing unique insights to global consumer and B2B brands”, said Mathijs Robbens, General Partner at Connected Capital. “More importantly, we are impressed by the team who have been able to scale ChannelSight to become a market leader in both Europe and the US.”

Hundreds of global brands in 65 countries now use ChannelSight technology to help users frictionlessly move from the brand’s digital content to retailers where they can purchase the product they are interested in. An advanced insights platform gives brands access to unique business intelligence that enables future budget allocation to be optimised, and increases the ROI brands gain from their content and campaigns.

“ChannelSight is modernising how brands drive profitable user engagement with their content across digital channels and markets”, said John Beckett, CEO and co-founder of ChannelSight. “This new round of investment will enable us to accelerate the delivery of innovative new product lines and increase our global reach. We’re excited about the impact this will have for our clients and are proud to partner with Connected Capital and our existing investors to build further momentum and continue our strong annual growth.” ChannelSight currently employs 70 people and is now hiring for an additional 30 roles across product, marketing, sales and engineering in their Dublin, Brasov and Thessaloniki offices. “We believe that ChannelSight is a truly exciting company with global ambitions and market defining potential.”, said John Flynn, Managing Partner at ACT Venture Capital. “Having shown significant growth, we have confidence the team is in place to lead the expansion. ACT is delighted to support the acceleration of this expansion and will continue to support Channelsight’s global ambitions.”

Categories: News

Tags:

HarbourVest Partners Expands Senior Team with Promotions to Managing Director, Principal, and Senior Vice President

Harvourvest

BOSTON– March 7, 2018 — HarbourVest Partners, a global private markets asset manager, today announced its 2019 promotions, including five new Managing Directors: Rich Campbell, Minjun Chung, Edward Holdsworth, Craig MacDonald, and Laura Thaxter; as well as eight new Principals and three Senior Vice Presidents. These promotions recognize team members whose expertise contributes to the success of HarbourVest and its clients across the Americas, Europe, and Asia Pacific

“It has long been our belief that our people are at the heart of our business and our greatest asset,” said Pete Wilson, Managing Director, HarbourVest. “We continue to develop talent and invest in our team to deliver the best possible results for our clients across our business and the regions in which we operate.”

In addition to the Managing Directors and Principals, this round of promotions also included 13 Vice Presidents.

Promotions to Managing Director, Principal, and Senior Vice President included:

MANAGING DIRECTORS
Rich Campbell
Minjun Chung
Edward Holdsworth
Craig MacDonald
Laura Thaxter

PRINCIPALS AND SENIOR VICE PRESIDENTS
Principals
Abuzar Anaswala
Emily Archer
Matt Cheng
Gonçalo Ferreira
Dominic Goh
Jackie Peradotto
Eric Simas
Martin Yung

Senior Vice Presidents
Aliza Firestone-Goren
Jason Frigiani
Dave Rule

For more information on the HarbourVest team, please visit:https://www.harbourvest.com/team.

ABOUT HARBOURVEST

HarbourVest is an independent, global private markets investment specialist with 36 years of experience and more than $58 billion in assets under management, as of December 31, 2018. The Firm’s powerful global platform offers clients investment opportunities through primary fund investments, secondary investments, and direct co-investments in commingled funds or separately managed accounts. HarbourVest has more than 500 employees, including more than 100 investment professionals across Asia, Europe, and the Americas. This global team has committed more than $35 billion to newly-formed funds, completed over $19 billion in secondary purchases, and invested over $9 billion directly in operating companies. Partnering with HarbourVest, clients have access to customized solutions, longstanding relationships, actionable insights, and proven results.

CONTACTS

Andrew Hopkins
617-348-8372
AHopkins@Harbourvest.com

Categories: People

GI Partners Announces Strategic Minority Investment by Blackstone

Blackstone

San Francisco, March 6, 2019 – GI Partners, a leading middle-market alternative asset manager, announced today that funds affiliated with Blackstone’s (NYSE: BX) Strategic Capital Group has acquired a minority stake in the firm.

The investment provides GI Partners with balance sheet capital to reinvest in the business and engage in strategic initiatives. Terms of the transaction were not disclosed.

Rick Magnuson, Founder and Executive Managing Director of GI Partners, said: “This investment is a testament to the strength of the people and processes which have driven our success over the last two decades. We look forward to leveraging the partnership with Blackstone as we continue to grow and diversify the business for the benefit of our investors.”

Scott Soussa, Head of Blackstone Alternative Asset Management’s Strategic Capital Group, which specializes in acquiring long-term interests in alternative managers, said: “Under Rick’s leadership, GI Partners has established itself as a leading firm in middle-market private equity and real estate investing. Their differentiated sourcing capabilities and strong operating expertise have led to sustained success since their founding and position the firm well for continued growth.”

Evercore served as financial advisor to GI Partners. Kirkland & Ellis served as legal counsel to GI Partners and Simpson Thacher served as legal counsel to Blackstone.

About GI Partners
Founded in 2001, GI Partners is a private investment firm based in San Francisco, California. The firm has raised over $17 billion in capital from leading institutional investors around the world to invest in private equity, real estate, and data infrastructure strategies. The private equity team invests primarily in companies in the Healthcare, IT Infrastructure, Services, and Software sectors. The real estate team invests across a broad range of platforms and strategies. The data infrastructure team invests primarily in hard asset infrastructure businesses underpinning the digital economy. For more information on GI Partners and its entire portfolio, please visit www.gipartners.com.

About Blackstone Alternative Asset Management
Blackstone Alternative Asset Management (BAAM®), Blackstone’s Hedge Fund Solutions platform, is the world’s largest discretionary investor in hedge funds, with approximately $78 billion in assets under management. BAAM manages a diversified set of businesses including a customized solutions business, a special situations platform, a hedge fund seeding business, an open-ended mutual fund platform and a business that purchases stakes in established alternative asset managers. In all of BAAM’s business lines, it carefully selects and partners with fund managers across a variety of asset classes and strategies to create solutions for its investors. Through its sharp focus on clients’ goals, a rigorous due-diligence process and access to Blackstone’s global insights, BAAM strives to generate attractive risk-adjusted returns across market cycles while preserving capital during stressed market environments.

Contacts
GI Partners
Chris Tofalli
Chris Tofalli Public Relations
914-834-4334
chris@tofallipr.com

Gretchen Robinson
Investor Relations
415-688-4800
grobinson@gipartners.com

Blackstone
Paula Chirhart
+1 (212) 583-5263
paula.chirhart@blackstone.com

Categories: News

Tags:

Volpi Capital expands its investment team with the appointment of Erik Berggren

Volpi Capital

London, 6 March 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private equity firm, is pleased to announce that Erik Berggren has joined its investment team. Erik’s appointment takes Volpi’s total headcount to 11, including 7 investment professionals.

Working as part of Volpi’s investment team, Erik will help source and execute deals across Europe, particularly in the Nordic region. In addition, he will also work with current and prospective portfolio company management teams to help them realise their growth objectives.

Erik, whose background includes investment banking and consulting, joins from Arma Partners, where he provided M&A advisory services to technology companies for three years. During his time at Arma Partners, Erik advised on transactions predominantly in the Nordic, German and UK markets. Prior to this, he worked at Deloitte in London, advising private equity houses and their portfolio companies.

Erik is Swedish – taking Volpi’s spread of nationalities to 9 – and holds a first class undergraduate degree from King’s College, London.

Commenting on the appointment, Marco Sodi from Volpi Capital said: “We are delighted that Erik has joined Volpi. Erik brings significant technology sector expertise, which aligns well with our thesis driven origination and investment approach, targeting investment in ambitious businesses using technology to disrupt traditional business models and processes.

“Since 2016, we have established a strong, internationally diverse and talented team that will deliver long-term success. We look forward to further additions to the team over the next twelve months, as we continue to expand and develop as a specialist European lower mid-market firm.”

Erik added: “This is a great opportunity to join a firm that is on a clear upwards trajectory and which has made strong progress in a short period of time. I was particularly drawn to Volpi’s ‘pick-your-partner’ approach when working with company owners and management teams, their industry specialist focus and their entrepreneurial and ambitious culture.

“I look forward to working with the team, the portfolio company management teams, as well as our limited partners.”

Volpi successfully closed its maiden fund – Volpi Capital Fund I – at its €185m hard cap in April 2018. Volpi’s current portfolio companies are CycloMedia, Version 1, Medinet and Digital Barriers.

Volpi was founded in 2016 by Crevan O’Grady and Marco Sodi.

About Volpi Capital

Volpi Capital is a specialist European lower mid-market private equity firm. Volpi has a thesis-driven approach targeting ambitious businesses using enabling technologies to disrupt traditional B2B value chains. Volpi typically invests €25-75 million of equity in businesses with enterprise values between €50 million and €200 million and seeks to drive transformative growth through international expansion and consolidation. The firm, which was founded in 2016 by Crevan O’Grady and Marco Sodi, closed its first fund (Volpi Capital Fund I) in April 2018 with commitments of €185 million.

http://www.volpicapital.com

For all media enquiries, please contact:

Instinctif Partners

Ross Gillam/Justine Crestois

+44 20 7457 2020

volpi@instinctif.com

Categories: People

Tags:

HQ Equita strengthens leadership team and initiates a generation change

HQ Capital

Bad Homburg, 6 March 2019 – HQ Equita, the mid-cap buyout arm of HQ Capital and a successful partner for small and medium-sized enterprises in the German-speaking area for about three decades, strengthens its management team and initiates the generational change. Christine Weiß, who joined HQ Equita in 2006 and became a Partner in 2014, is appointed Managing Director of HQ Equita. Frank Schäfer, Matthias Tabbert and Florian Wiemken are appointed Partners.

 

Frank Schäfer has been part of HQ Equita’s Investment Team since 2012. During this time, he was involved in the management and successful sales of ISOLITE and MEN. Most recently, he completed the acquisitions of r2p Group and Open Access (Sydney).

 

Matthias Tabbert has over ten years of experience in the mid-cap buyout business and joined HQ Equita’s Investment Team in early 2011. He has worked on various portfolio company acquisitions and exits, including WindStar Medical and Well Plus Trade.

 

Florian Wiemken has been a member of HQ Equita’s Investment Team since 2012 and has been involved in numerous transactions over the past seven years, including the acquisition, management and successful sale of Rovema Group.

 

Torsten Krumm, who has been responsible for leading the generation change at HQ Equita and has successfully strengthened its management team, will head the Investment Committee in a new role in the future.

 

The team has been working together successfully for many years and has been instrumental in the development of HQ Equita. With the generational change and the support of Managing Director and Partner Hans J. Moock, who has been working for HQ Equita for more than 13 years, continuity in the management of HQ Equita will be ensured.

 

“As an experienced and proven team, we are optimally positioned to further develop HQ Equita. Together, we will continue to consistently realize attractive investment opportunities and support the growth strategies and development of our portfolio companies in a sustainable manner”, says Christine Weiß.

 

“The generation change is the next logical step in HQ Equita’s onward development as a specialist for primary investments in SMEs,” says Dr Bernd Türk, Managing Director of HQ Capital. “These appointments lay the foundation for stability and continuity. I am pleased to work with this dynamic team.”

 

With the strengthened management team, HQ Equita intends to expand its existing relationships with entrepreneurs, enhance its investment focus and raise its profile in the market.

Categories: People

Tags:

Bluebee receives Health Data Hosting (HDS) accreditation

Rijswijk, The Netherlands: 6 March 2019 – Bluebee, a global bioinformatics solutions provider, has been awarded the HDS:2018 certification for its Information Security Management System (ISMS). The Hébergeurs de Données de Santé or Health Data Hosting (HDS) accreditation is required for entities hosting personal health data governed by French laws. The British Standards Institution (BSI) conducted the audit and confirmed Bluebee’s compliance with all requirements and controls defined by the French Agency, Agence des Systèmes d’Information Partagés de Santé (ASIP).

Bluebee’s ISMS governs HDS outsourcer host activities, including development, management, support and maintenance of cloud infrastructure and cloud-based information systems that process large volumes of omics and health data. The achievement of this accreditation reaffirms Bluebee’s continued commitment to providing the most secure and reliable data management solutions to clinical laboratories, diagnostic assay manufacturers and population genomics initiatives.

Categories: News

Tags:

Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update

GIlde Healthcare

IRVINE, CA – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial results for the fourth quarter and year ended December 31, 2018, and provided an update on operational initiatives.

Recent Business Highlights

  • In Q4, commercial sales of the miniaturized rechargeable Axonics r-SNM® System totaled $0.5 million.
  • On February 11, filed full-body magnetic resonance imaging (“MRI”) data with the U.S. Food and Drug Administration (“FDA”) seeking conditional labeling for the miniaturized rechargeable Axonics r-SNM System.
  • On February 19, disclosed top-line six-month clinical results on the full cohort of patients for the ARTISAN-SNM pivotal clinical study of the Axonics r-SNM System which indicated 90% of all implanted subjects met the efficacy endpoint and that the study met all primary and secondary endpoints.
  • On February 21, filed a detailed six-month clinical study report with the FDA on the results of the ARTISAN-SNM pivotal clinical study.
  • On February 22, announced CE Mark approval for full-body MRI conditional labeling in Europe for the Axonics r-SNM System, making the Axonics system the first SNM device that allows a safe full-body MRI scan while implanted.
  • On March 4, appointed Michael H. Carrel to the Board of Directors.

Raymond W. Cohen, CEO of Axonics, commented, “We view the generation of $0.5 million of revenue in the fourth quarter, serving a handful of customers with a small team of sales professionals, to be a harbinger of things to come. We are seeking measurable market share gains in 2019 from our two primary markets in Europe, the United Kingdom and the Netherlands. The accounts we have secured in these markets are exceeding our expectations in terms of the percentage of SNM implants using the Axonics system. Moreover, we now have the only SNM device with full-body MRI labeling, an advantage that should aid us in gaining further traction.”

Cohen continued, “Our primary focus continues to be gaining FDA approval in the shortest possible timeframe. To that end, and based on interaction with the FDA, we determined our best course of action was to further enrich our current literature-based PMA with the full cohort of ARTISAN-SNM study data as well as the full-body MRI data. As we advance our regulatory strategy, we continue to press forward on our initiative to be fully prepared to execute a broad, fully staffed U.S. launch upon FDA approval. We are building a world-class team and have been pleased that many experienced neuromodulation and urology professionals view Axonics as an attractive place to work that represents an exciting career opportunity. Overall, we are making excellent progress on our key operational objectives.”

Fourth Quarter 2018 Financial Results

Net revenue was $0.5 million in the fourth quarter ended December 31, 2018, derived from the sale of the Company’s r-SNM Systems to customers in Europe and Canada, as compared to no net revenue for the same period of last year.

Gross margin was 50.4% in the fourth quarter of 2018.

Operating expense was $9.7 million for the fourth quarter of 2018, as compared to $4.9 million in the prior-year quarter. This increase was primarily due to higher personnel costs across the organization as well as the costs of operating as a public company.

Net loss for the fourth quarter of 2018 was $9.7 million as compared to $4.9 million in the prior-year quarter. Net loss per share for the fourth quarter of 2018 was $0.50 per share.

As of December 31, 2018, cash, cash equivalents and short-term investments were $157.5 million.

Dan L. Dearen, Axonics President and CFO, said, “We have been actively hiring commercial, operations, regulatory, and quality personnel to ensure we execute on our strategy of fielding a full complement of sales and marketing professionals with sufficient inventory on hand to support a U.S. launch upon FDA approval. To date, we have hired 60 well-qualified sales professionals, 11 regional sales directors and 12 clinical specialists, putting us ahead of schedule and in a good position with the build out of our team and its ability to execute if the approval were to come before our initial projection. The accelerated costs associated with that shift puts us in the best position to achieve our commercial goals when approved.”

Full Year 2018 Financial Results

Net revenue was $0.7 million in fiscal year 2018, derived from the sale of the Company’s r-SNM Systems to customers in Europe and Canada, as compared to $0.1 million in fiscal year 2017.

Gross margin was 49.7% in fiscal year 2018, compared to 7.9% gross margin in fiscal year 2017. The increase in gross margin is primarily due to country and product mix.

Operating expense was $32.5 million in fiscal year 2018, as compared to $18.2 million in fiscal year 2017. This increase was primarily due to increases in personnel, regulatory submissions and clinical development, contract fabrication and manufacturing, and legal costs.

Net loss for the year was $32.5 million as compared to $18.1 million in the prior year. Net loss per share for fiscal year 2018 was $4.64 per share.

Webcast and Conference Call

Today, on Tuesday, March 5, 2019, at 4:30 p.m. Eastern Time, the Company will host a conference call with the investment community to discuss the financial results and recent business developments.
Interested parties may access the live call via telephone by dialing (866) 687-5771 (U.S.) or (409) 217-8725 (International) and using conference ID 3386378.

A live webcast of the call may be accessed by visiting the Events & Presentations page of the investors section of the Company’s website at ir.axonicsmodulation.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website for 90 days.
About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, is focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for patients with urinary and bowel dysfunction. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence. SNM therapy is a well-established treatment that has been widely used and reimbursed in Europe and the U.S. for the past two decades. The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain CE mark for full-body MRI conditional labeling. Premarket Approval (PMA) for the r-SNM System is currently pending with the U.S. FDA. For more information, visit the Company’s website at www.axonicsmodulation.com.

Forward Looking Statements

Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

 

Contacts:

Axonics’ Contact

Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
ir@axonics.com

Investor & Media Contact

W2Opure
Matt Clawson, +1-949-370-8500
mclawson@w2ogroup.com

 

Categories: News

Tags:

Gaw Capital Partners Wins Two Awards at PERE Awards 2018 – Asia’s Deal of the Year & Industry Figure of the Year

Gaw Capital

HONG KONG, March 5, 2019 – Gaw Capital Partners is delighted to have been awarded Asia’s ‘Deal of the Year’ for its HK$23 billion acquisition of 17 Hong Kong shopping centres from Link REIT, which was completed in February 2018, and Asia’s ‘Industry Figure of the Year’ for Goodwin Gaw at this year’s PERE Awards.
The firm was also very pleased to have been a runner up for Global ‘Office Investor of the Year’, Global ‘Retail Investor of the Year’, ‘Capital Raise of the Year’ in Asia for its Gateway Real Estate Fund VI and ‘Firm of the Year’ in Asia and China respectfully.
The awards and recognitions follow another successful year for Gaw Capital, in which it closed major deals in China, Australia and Japan. These include the acquisitions of a further 12 Hong Kong shopping centres from Link REIT, Shanghai’s Ocean Towers and four premium Grade A offices at Shanghai MixC through its funds under management.
During 2018, the firm raised additional US$4.8 billion of equity commitments, acquired 24 projects in 15 cities and disposed 7 projects in 8 cities through its funds under management. The total deal transaction volume exceeds US$11.9 billion globally.
Mr. Goodwin Gaw, Chairman and Management Principal at Gaw Capital Partners, commented, “It is an honor to have received these accolades and recognitions, which have been the result of our strong teamwork culture. The awards reflect the recognition globally of Gaw Capital’s creativity and capabilities on some of the most complex but high-potential real estate transactions. We thank PERE for the awards and express our heartfelt gratitude to our LPs, partners and team for your continuous support, partnership and hard work.”
The Global PERE Awards recognize significant highlights in the global real estate industry and is highly respected across the global real estate private equity industry.

 

Categories: News

Tags: